- Uterine fibroids are also known as leiomyoma or myomas, which can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus. A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level
- The demand for uterine fibroid treatments is significantly driven by the rising prevalence of uterine fibroids, increasing awareness through women’s health initiatives, and technological advancements in minimally invasive treatment options such as MR-guided focused ultrasound and laparoscopic procedures
- North America is expected to dominate the Uterine Fibroids market with a share of 36.4%, due to its advanced healthcare infrastructure, widespread use of modern treatment techniques, and strong presence of key market players specializing in gynecological health.
- Asia-Pacific is expected to be the fastest growing region in the Uterine Fibroids market during the forecast period due to rapid improvements in healthcare infrastructure, increased awareness about reproductive health, and a higher number of treatment procedures being performed
- Subserosal Fibroids segment is expected to dominate the market with a market share of 34.5% due to its high prevalence and frequent need for clinical intervention. This type of fibroid is more likely to cause noticeable symptoms, leading to earlier diagnosis and treatment. Despite the emergence of newer non-invasive therapies, surgical management of subserosal fibroids remains widely adopted due to its established clinical outcomes, ease of procedural planning, and minimal requirement for specialized infrastructure. Its predictable growth pattern and accessibility during surgery continue to support its leading role in fibroid treatment.
